Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Focal therapy vs active surveillance in men with low-risk prostate cancer

Posted by on May 15, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the safety and efficacy of focal therapy compared to active surveillance in men with low-risk prostate cancer. The authors concluded that focal therapy was a safe and effective treatment option in men with low-risk prostate cancer. The also suggested that this treatment could be an option to avoid more...

Read More

Is active surveillance suitable for prostate cancer patients regardless of age?

Posted by on May 15, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the relationship between patient age and active surveillance outcomes in prostate cancer (PC). This study concluded that younger patients undergoing AS were less likely to see an increased Gleason score and progression.  Some background Early stage PC that has not yet spread is often not treated...

Read More

Proteins in the prostate gland can help predict disease recurrence after surgery

Posted by on May 15, 2017 in Prostate cancer | 0 comments

In a nutshell This study examined if the collections of proteins in the prostate can predict prostate surgery outcomes. Authors found that protein analysis was a significant predictor of disease recurrence and metastasis (cancer spread) after surgery. Some background Prostate surgery is a first-line treatment option for prostate cancer. It has...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide.  Some background Treatment for metastatic...

Read More

Which prostate cancer patients are at risk of skeletal related events?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated whether the likelihood of developing skeletal related events (SREs) could be determined depending on the site of metastasis at diagnosis and other factors in older patients with prostate cancer. The study concluded that the likelihood of developing an SRE was similar among different sites of metastasis, except...

Read More

The use of circulating tumor cells in predicting survival in chemotherapy patients

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to investigate if circulating tumor cells (CTC) levels in the blood could be used to determine the outcome for metastatic castration resistant prostate cancer patients. This study concluded that CTC levels could be used to predict survival in these patients.  Some background Treatment for metastatic...

Read More

The timing of first biopsy and its effect on prostate cancer reclassification

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance.  The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...

Read More